<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01847794</url>
  </required_header>
  <id_info>
    <org_study_id>CGOG5002</org_study_id>
    <nct_id>NCT01847794</nct_id>
  </id_info>
  <brief_title>HER2 Positive CTC in Advanced Gastric Cancer</brief_title>
  <acronym>AGC-HER2CTC</acronym>
  <official_title>Clinical Significance of HER2 Positive Circulating Tumor Cells(CTCs) in the Peripheral Blood of Patients With Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <brief_summary>
    <textblock>
      To identify the correlation of HER2 expression in tissue and peripheral CTC. to identify the&#xD;
      HER2 expression in CTCs with clinical prognosis in advanced/metastatic gastric cancer.&#xD;
&#xD;
      Confirm the presence of CTCs are sensitive for monitoring response to chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HER2 positive CTC</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical significance of HER 2 positive CTC</measure>
    <time_frame>2years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>HER2 Positive Advanced Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>chemotheropy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cell Search® CTC epithelial kit</intervention_name>
    <description>Collect peripheral blood sample of 50 gastric cancer patients pre-chemotherapy and post two cycles of chemotherapy(response evaluation).&#xD;
Blood samples will be transferred to central lab to detect HER2 positive CTCs by Cellsearch epithelial kit.&#xD;
Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.</description>
    <arm_group_label>chemotheropy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Having signed informed consent&#xD;
&#xD;
          -  Age≥ 18 years old&#xD;
&#xD;
          -  HER2 overexpression confirmed by IHC or ISH (IHC 3+,or IHC2+/ISH+)&#xD;
&#xD;
          -  Histologically confirmed gastric adenocarcinoma&#xD;
&#xD;
          -  Unresectable recurrent or metastatic disease&#xD;
&#xD;
          -  Previous neo-adjuvant or adjuvant treatment for gastric cancer, if applicable, more&#xD;
             than 6 months&#xD;
&#xD;
          -  Measurable disease according to the RECIST criteria&#xD;
&#xD;
          -  Karnofsky performance status ≥70&#xD;
&#xD;
          -  Life expectancy of ≥3 month&#xD;
&#xD;
          -  No prior radiotherapy except radiotherapy at non-target lesion of the study more than&#xD;
             4 weeks&#xD;
&#xD;
          -  ALT and AST&lt;2.5 times ULN (≤5 times ULN in patients with liver metastases)&#xD;
&#xD;
          -  Serum albumin level ≥3.0g/dL&#xD;
&#xD;
          -  Serum AKP &lt; 2.5 times ULN&#xD;
&#xD;
          -  Serum creatinine &lt;ULN, and CCr &lt; 60ml/min&#xD;
&#xD;
          -  Bilirubin level &lt; 1.5 ULN&#xD;
&#xD;
          -  WBC&gt;3,000/mm3, absolute neutrophil count ≥2000/mm3, platelet&gt;100,000/mm3, Hb&gt;9g/dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous systemic therapy for metastatic gastric cancer&#xD;
&#xD;
          -  Surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry&#xD;
             Contraindications of nuclear magnetic resonance image such as fitment of cardiac&#xD;
             pacemaker , nerve stimulator, or aneurysm clip, and metallic foreign body in eye ball&#xD;
             and so on.&#xD;
&#xD;
          -  Allergic constitution or allergic history to protium biologic product or any&#xD;
             investigating agents.&#xD;
&#xD;
          -  Severe heart disease or such history as recorded congestive heart failure,&#xD;
             uncontrolled cardiac arrhythmia, angina pectoris needing medication, cardiac valve&#xD;
             disease, severe abnormal ECG findings, cardiac infarction , or retractable&#xD;
             hypertension.&#xD;
&#xD;
          -  Pregnancy or lactation period&#xD;
&#xD;
          -  Other previous malignancy within 5 year, except non-melanoma skin cancer&#xD;
&#xD;
          -  Legal incapacity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>lin shen, MD. PhD</last_name>
    <phone>(86)10-88196175</phone>
    <email>lin100@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking cancer hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>xiaotian zhang, MD. PhD</last_name>
      <phone>(86)10-88196561</phone>
      <email>zhangxtxx@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>jifang gong, MD. PhD</last_name>
      <phone>(86)10-88196561</phone>
      <email>gongjifang@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>April 29, 2013</study_first_submitted>
  <study_first_submitted_qc>May 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2013</study_first_posted>
  <last_update_submitted>May 2, 2013</last_update_submitted>
  <last_update_submitted_qc>May 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>Director of GI oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

